INTERSECT ENT SHAREHOLDERS HAVE AN OPPORTUNITY TO RECOVER THEIR INVESTMENT LOSSES

Intersect ENT, Inc.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Intersect ENT, Inc. (NASDAQ: XENT) between August 1, 2018, and May 6, 2019. The lawsuit seeks to recover Intersect ENT shareholders’ investment losses.

If you purchased shares of Intersect ENT between August 1, 2018 and May 6, 2019, and would like to join the action, please click “Join Class Action” above.

New York, New York – Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Intersect ENT, Inc. (“Intersect ENT” or the “Company) (NASDAQ: XENT) between August 1, 2018, and May 6, 2019, both dates inclusive (the “Class Period”). The lawsuit, filed in the United States District Court for the Northern District of California, seeks to recover damages for Intersect ENT shareholders under the federal securities laws.

According to the lawsuit, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclosed that (1) that Intersect ENT lacked adequate reimbursement representatives to ensure physicians had access to SINUVA; (2) that, as a result, Intersect ENT’s sales force would focus on ensuring reimbursement; (3) that, as a result, Intersect ENT’s sales representatives were less focused on driving sales; (4) that physicians were less likely to adopt Intersect ENT’s SINUVA due to transaction costs associated with seeking reimbursement; (5) that the Company would increase staffing to address these issues; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff in the Intersect ENT class action, you must move the court no later than July 15, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you take no action, you may remain an absent class member.

If you are interested in discussing your rights as an Apple investor or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.

Bernstein Liebhard LLP has pursued hundreds of securitiesconsumer and shareholder rights cases and recovered over $3.5 billion for its clients.  The Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and been listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Joe Seidman Bernstein Liebhard LLP https://www.bernlieb.com (877) 779-1414 seidman@bernlieb.com